

4-6-10 Koishikawa, Bunkyo-ku, Toky

Phone: 03- 3817-5120

Fax: 03-3811-3077

olutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patientsApnil JEDs ai Co., Hisai Withdraw Application for Artilitips la Indication of

®

## for Treatment of Severe Alzheimer's Disease in Europe

Eisai Limited (Headquaters: London, Managing Director: Paul Hooper), the U.K. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), today announced that the company has tentatively withdrawn its application for an additional indication for *Aricept*<sup>®</sup> in the treatment of severe Alzheimer's disease, submitted through the mutual recognition procedure in Europe. Eisai will discuss the matter with the European regulatory authorities and review possibilities for resubmission.

The *Aricept*®'s indication in the treatment of severe Alzheimer's disease has already been approved in the USA, India, New Zealand and Philippines. In addition, the application has been submitted in Japan.